What medication can be added to buspirone to manage anxiety and depression?

Adding Medication to Buspirone for Anxiety and Depression

When buspirone alone is insufficient for managing anxiety and depression, add a selective serotonin reuptake inhibitor (SSRI) such as escitalopram, fluoxetine, or sertraline, or alternatively add bupropion SR. This recommendation is based on the most robust evidence showing that buspirone functions effectively as an augmentation agent to SSRIs rather than as a standalone treatment for depression 1, 2.

The Evidence-Based Approach

Primary Strategy: SSRI + Buspirone Combination

The FDA label clearly indicates that buspirone is approved for anxiety management and that "many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms" 2. However, buspirone is not FDA-approved as a primary antidepressant—it works best when augmenting other antidepressants.

The most recent high-quality evidence from 2025 demonstrates that adjunctive buspirone therapy with SSRIs or SNRIs significantly improved both anxiety and depression scores over 12 weeks 3. In this multicenter prospective study of 161 patients:

• Hamilton Anxiety scores decreased from 25.2 to 15.4 (p < 0.001)
• Hamilton Depression scores decreased from 19.4 to 12.7 (p < 0.001)
• Response rate was 39.1% with only 3.7% adverse events
• Importantly, treatment response was independent of buspirone dosage or baseline symptom severity

Alternative Strategy: Bupropion SR + Buspirone

The 2023 American College of Physicians guideline from the landmark STAR*D trial found that augmentation of citalopram with either bupropion SR or buspirone showed similar efficacy 1. However, discontinuation due to adverse events was significantly lower with bupropion SR (12.5%) compared to buspirone augmentation (20.6%; P < 0.001) when both were used as augmentation agents.

Practical Implementation Algorithm

If Starting Fresh with Anxiety + Depression:

1. Initiate an SSRI first (escitalopram 10-20 mg, fluoxetine 20-40 mg, or sertraline 50-200 mg)
2. Add buspirone after 2-6 weeks if response is inadequate
   • Start buspirone at 7.5 mg twice daily
   • Titrate to 15-30 mg twice daily based on response 3
   • Maximum dose: 60 mg/day divided

If Buspirone is Already Prescribed:

1. Add an SSRI as the primary antidepressant
   • Escitalopram 10-20 mg daily, OR
   • Fluoxetine 20-40 mg daily, OR
   • Sertraline 50-200 mg daily
2. Continue buspirone at current dose (typically 15-30 mg twice daily)

Critical Drug Interactions to Monitor

The FDA label warns of significant interactions 2:

• Nefazodone: Increases buspirone levels up to 50-fold in AUC—if combining, reduce buspirone to 2.5 mg daily
• Azole antifungals (itraconazole, ketoconazole): Increase buspirone 13-19 fold—reduce to 2.5 mg daily
• Grapefruit juice: Causes 2-fold increase—advise patients to avoid large amounts
• CYP3A4 inducers (rifampin, carbamazepine, phenytoin): Decrease buspirone by 90%—may need dose increase

Evidence Quality and Nuances

The evidence supporting buspirone augmentation of SSRIs is stronger than buspirone monotherapy for depression. Multiple studies from 1993-2025 consistently show 43-63% response rates when buspirone augments SSRIs in treatment-refractory depression 4, 5, 6, 7.

A critical caveat: One 2001 placebo-controlled study found that buspirone augmentation was only significantly superior to placebo in patients with severe depression (MADRS >30), not in the overall population 4. This suggests buspirone augmentation may be most beneficial for more severe presentations.

The 2020 study found that cognitive enhancement from buspirone augmentation was greater in MDD patients WITHOUT atypical features 8, suggesting phenotypic differences may predict response.

Common Pitfalls to Avoid

• Don't use buspirone as monotherapy for major depression—it's not FDA-approved for this and evidence supports its role as augmentation 2
• Don't combine with strong CYP3A4 inhibitors without dose reduction—risk of severe side effects 2
• Don't expect immediate results—significant improvement may take 1-4 weeks 3, 4
• Don't forget the 48-hour washout before catecholamine testing—buspirone interferes with metanephrine assays 2

Dosing Specifics

Based on the 2025 study, treatment response was independent of buspirone dosage 3, suggesting that starting at lower doses (15-30 mg/day divided) may be as effective as higher doses while minimizing side effects. The STAR*D data showed similar efficacy across augmentation strategies, reinforcing that the choice of SSRI partner matters less than ensuring adequate dosing of both agents 1.